Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease [2]

Annals of the Rheumatic Diseases

Volumn 61, Issue 6, 2002, Pages 560-561

  Triolo, G ^a   Vadala M ^a   Accardo Palumbo, A ^a   Ferrante, A ^a   Ciccia, F ^a   Giardina, E ^a   Citarrella, P ^a   Lodato, G ^a   Licata, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYDRIATIC AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; EYE DISEASE; HUMAN; IMMUNE RESPONSE; LETTER; MALE; PRIORITY JOURNAL; SIDE EFFECT; TH1 CELL; TREATMENT OUTCOME; VISUAL ACUITY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; HUMANS; MALE; RECURRENCE; RETINITIS;

EID: 0036095179     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.6.560     Document Type: Letter

References (4)

1. The rate of visual loss in Behçet's disease
2. Production of TNF alpha and II-1 in active Behçet's disease
3. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL)6, IL-8 and increased neutophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects
4. Th1 polarization of the immune response in Behçet's disease: A putative role of interleukin-12